Liquidia Technologies (LQDA) AI Stock Analysis

• Market Cap: $1.93B
• Dividend Yield: N/A
• Average Volume (3M): 2.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: 30.20%
• EPS Growth: -7.22%
• Country: US
• Employees: 170
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 86,091,450
• 10 Day Avg. Volume: 2,018,949
• 30 Day Avg. Volume: 2,657,949
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 54.30
• Enterprise Value/Gross Profit: 77.18
• Enterprise Value/Ebitda: -8.48
• 1Y Price Target: $40.75
• Price Target Upside: 76.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 47 Neutral
• Price Target: $22.50 ▼(-2.81% Downside)

Liquidia Technologies' overall score is driven by significant financial challenges, including persistent losses and high leverage. The successful launch of YUTREPIA and strong cash position are positives, but technical indicators and valuation metrics remain weak. The stock's future performance hinges on overcoming financial instability and litigation outcomes.

Positive Factors

Successful Product Launch

The successful launch of YUTREPIA indicates strong market demand and effective commercialization strategy, supporting future revenue growth.

Strong Financial Position

A solid cash position provides financial stability and flexibility to invest in growth opportunities and manage operational challenges.

Expansion Plans

Capacity expansion plans indicate confidence in product demand and support long-term growth by meeting future market needs.

Negative Factors

High Leverage

High leverage can strain financial stability, limiting the company's ability to invest in growth and manage economic downturns.

Negative Cash Flow

Negative cash flow indicates challenges in covering operational expenditures, potentially impacting long-term sustainability.

Pending Litigation Outcome

Uncertainty in litigation outcomes can affect market position and future revenue, posing risks to strategic planning and investor confidence.

Liquidia Technologies Business Overview & Revenue Model

Company Description

Liquidia Technologies, Inc. (LQDA) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for patients with serious diseases. The company specializes in utilizing its proprietary PRINT® (Particle Replication in Non-wetting Templates) technology to create precisely engineered drug formulations, particularly in the areas of pulmonary hypertension and other respiratory diseases. Liquidia's core products include Yutrepia, a drug designed to treat pulmonary arterial hypertension, and its pipeline includes several other candidates targeting unmet medical needs.

How the Company Makes Money

Liquidia Technologies generates revenue primarily through the commercialization of its products, including Yutrepia, which is sold directly to healthcare providers and pharmacies. The company also earns revenue through partnerships and collaborations with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales of partnered products. Additionally, Liquidia may receive funding from grants or government contracts aimed at supporting the development of its technology and drug candidates.

Liquidia Technologies Financial Statement Overview

Summary

Liquidia Technologies faces significant financial challenges with persistent losses and negative cash flows. Despite a slight revenue increase, the company struggles with profitability and high leverage, though liquidity is supported by cash reserves.

Income Statement

Liquidia Technologies has shown a marginal increase in revenue over the recent period, but it remains unprofitable with significant negative EBIT and net income. The firm is struggling with negative profit margins, indicating challenges in achieving profitability. However, the slight revenue growth is a positive indicator of potential market demand.

Balance Sheet

The company's balance sheet reflects high leverage with a substantial debt-to-equity ratio due to negative equity. This indicates a risk in financial stability. Additionally, the negative equity ratio signifies a challenging financial position, though the liquidity position is supported by substantial cash and cash equivalents.

Cash Flow

Liquidia's cash flow situation shows substantial negative free cash flow, indicating challenges in covering operational expenditures. However, the company's ability to raise financing is a positive aspect, showing some confidence from investors despite operating losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.32M	14.00M	17.49M	15.94M	12.85M	739.63K
Gross Profit	13.59M	8.12M	14.60M	13.08M	9.83M	501.92K
EBITDA	-123.78M	-115.71M	-70.05M	-34.72M	-27.91M	-55.79M
Net Income	-99.89M	-130.39M	-78.50M	-41.02M	-34.58M	-59.76M
Balance Sheet
Total Assets	257.41M	230.31M	118.33M	129.20M	93.73M	99.53M
Cash, Cash Equivalents and Short-Term Investments	173.42M	176.48M	83.68M	93.28M	57.49M	65.32M
Total Debt	50.91M	122.39M	49.54M	24.46M	16.08M	17.14M
Total Liabilities	242.22M	153.04M	71.04M	38.78M	28.46M	28.45M
Stockholders Equity	15.19M	77.28M	47.29M	90.42M	-309.58M	71.09M
Cash Flow
Free Cash Flow	-123.98M	-98.37M	-42.85M	-29.18M	-34.14M	-54.90M
Operating Cash Flow	-116.06M	-93.42M	-41.56M	-28.59M	-34.04M	-54.14M
Investing Cash Flow	-7.91M	-8.44M	-11.29M	-587.00K	-107.22K	247.91K
Financing Cash Flow	167.80M	194.66M	43.25M	64.96M	26.32M	63.42M

Liquidia Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.15
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LQDA, the sentiment is Positive. The current price of 23.15 is above the 20-day moving average (MA) of 23.04, below the 50-day MA of 24.83, and above the 200-day MA of 17.84, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 49.11 is Neutral, neither overbought nor oversold. The STOCH value of 28.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LQDA.

Liquidia Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADPT	―	$2.62B	-21.15	-57.55%	―	21.60%	44.48%
ARQT	―	$2.41B	―	-28.17%	―	129.21%	80.35%
RXRX	―	$2.63B	―	-86.34%	―	30.14%	-10.08%
OCUL	―	$2.44B	-9.02	-63.41%	―	-7.26%	-15.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LQDA	―	$1.93B	―	-363.16%	―	30.20%	-7.22%
IRON	―	$3.20B	―	-26.36%	―	―	-22.19%

Liquidia Technologies Corporate Events

Liquidia’s New Study on Inhaled Treprostinil: What Investors Need to Know

Liquidia Technologies is conducting a clinical study titled An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension. The study aims to assess the safety and tolerability of LIQ861, a dry powder inhalation form of treprostinil, in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). This research is significant as it explores a potentially safer and more effective treatment option for these conditions.

Liquidia Technologies’ Earnings Call Highlights YUTREPIA Success

The latest earnings call from Liquidia Technologies painted a picture of optimism and growth, with the company showcasing a robust start for its product YUTREPIA. The call highlighted impressive prescription numbers and conversion rates, alongside positive study results and a strong financial standing. However, challenges such as market entry blocks and reliance on channel inventory for initial revenue were also acknowledged.

Liquidia Corporation’s Strong Launch of YUTREPIA

Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, leveraging its proprietary PRINT technology to enhance drug delivery and efficacy. In its latest earnings report, Liquidia highlighted the successful commercial launch of YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), which has seen significant uptake since its FDA approval. The company reported over 900 unique patient prescriptions and 550 patient starts within 11 weeks of launch, reflecting strong demand and the potential for further growth as market access expands. Financially, Liquidia reported product revenue of $6.5 million for the quarter, with a net loss of $41.6 million, driven by increased commercialization efforts and ongoing litigation expenses. Looking ahead, Liquidia aims to scale access to YUTREPIA, expand clinical programs, and continue building value for patients and shareholders, supported by its recent financial agreements.